{
    "eid": "2-s2.0-85165915532",
    "title": "Tools and criteria to select patients with advanced Parkinson\u2019s disease for device-aided therapies: a narrative review",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Neurology",
            "@code": "2808",
            "@abbrev": "NEUR"
        },
        {
            "@_fa": "true",
            "$": "Neurology (clinical)",
            "@code": "2728",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Psychiatry and Mental Health",
            "@code": "2738",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Biological Psychiatry",
            "@code": "2803",
            "@abbrev": "NEUR"
        }
    ],
    "keywords": [
        "CSAI",
        "DBS",
        "Device-aided therapies",
        "LCIG",
        "Parkinson\u2019s disease",
        "Screening tools"
    ],
    "authors": [
        "Harmen R. Moes",
        "Tove Henriksen",
        "Jaros\u0142aw S\u0142awek",
        "Onanong Phokaewvarangkul",
        "Erik Buskens",
        "Teus van Laar"
    ],
    "citedby-count": 0,
    "ref-count": 84,
    "ref-list": [
        "Application of the \u20185-2-1\u2019 screening criteria in advanced Parkinson\u2019s disease: interim analysis of DUOGLOBE",
        "Genotype and phenotype in Parkinson\u2019s disease: Lessons in heterogeneity from deep brain stimulation",
        "Apomorphine and levodopa infusion therapies for advanced Parkinson\u2019s disease: Selection criteria and patient management",
        "Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach",
        "Validation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson\u2019s disease patients inadequately controlled on oral medications",
        "Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis",
        "Diagnosis and treatment of Parkinson disease: a review",
        "Advanced-stage Parkinson\u2019s disease: from identification to characterization using a nationwide database",
        "The new allocation era and policy",
        "Pharmacokinetics of Intravenously (DIZ101), subcutaneously (DIZ102), and intestinally (LCIG) infused levodopa in advanced parkinson disease",
        "Analysing the reasons for rejection of neurosurgery intervention in patients with Parkinson\u2019s disease referred to an extrapyramidal movement disorders clinic",
        "Neurologists\u2019 attitudes toward use and timing of deep brain stimulation",
        "Association of specialist involvement and quality of care for Parkinson\u2019s disease",
        "Late-stage Parkinson disease",
        "Validity and efficacy of screening algorithms for assessing deep brain stimulation candidacy in Parkinson\u2019s disease",
        "Transparent Reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement",
        "Disparities in deep brain stimulation use for Parkinson\u2019s disease in Ontario, Canada",
        "Use of a medication-based algorithm to identify advanced Parkinson\u2019s disease in administrative claims data: Associations with claims-based indicators of disease severity",
        "Initiation of pharmacological therapy in Parkinson\u2019s disease: when, why, and how",
        "Core assessment program for surgical interventional therapies in Parkinson\u2019s disease (CAPSIT-PD)",
        "European academy of neurology/movement disorder society-European section guideline on the treatment of Parkinson\u2019s disease: I",
        "Algorithms for the treatment of motor problems in Parkinson\u2019s disease",
        "How to improve patient education on deep brain stimulation in Parkinson\u2019s disease: the CARE monitor study",
        "The Parkinson pandemic - a call to action",
        "Deep brain stimulation for Parkinson\u2019s disease: timing and patient selection",
        "Use of advanced therapies for Parkinson\u2019s disease in Norway",
        "Adjunctive therapies in Parkinson\u2019s disease: how to choose the best treatment strategy approach",
        "Off-time treatment options for Parkinson\u2019s disease",
        "Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients",
        "Intercountry comparisons of advanced Parkinson\u2019s disease symptoms and management: analysis from the OBSERVE-PD observational study",
        "MNCD: a new tool for classifying Parkinson\u2019s disease in daily clinical practice",
        "Selecting candidates for deep brain stimulation in Parkinson\u2019s disease: the role of patients\u2019 expectations",
        "Personalized medicine approach in treating parkinson\u2019s disease, using oral administration of levodopa/carbidopa microtablets in clinical practice",
        "Potential utility of amantadine DR/ER in persons with Parkinson\u2019s disease meeting 5-2-1 criteria for device aided therapy",
        "Off time independently affects quality of life in advanced Parkinson\u2019s disease (APD) patients but not in non-APD patients: results from the self-reported Japanese quality-of-life survey of Parkinson\u2019s disease (JAQPAD) study",
        "Wearable sensors for advanced therapy referral in Parkinson\u2019s disease",
        "Access and use of device-aided therapies for Parkinson\u2019s disease in Denmark",
        "Gender gap in deep brain stimulation for Parkinson\u2019s disease",
        "Parkinson\u2019s disease in the Middle East, North Africa, and South Asia: consensus from the international Parkinson and movement disorder society task force for the Middle East",
        "Underutilization of deep brain stimulation for Parkinson\u2019s disease? A survey on possible clinical reasons",
        "Diagnostic test accuracy may vary with prevalence: implications for evidence-based diagnosis",
        "Lack of information and access to advanced treatment for Parkinson\u2019s disease patients",
        "Consensus on the definition of advanced Parkinson\u2019s disease: A neurologists-based Delphi study (CEPA study)",
        "Does the 5\u20132-1 criteria identify patients with advanced Parkinson\u2019s disease? Real-world screening accuracy and burden of 5\u20132-1-positive patients in 7 countries",
        "Parkinson\u2019s disease advanced therapies - a systematic review: More unanswered questions than guidance",
        "Device-aided therapies for advanced Parkinson disease: insights from an international survey",
        "Prevalence of advanced Parkinson\u2019s disease in patients treated in the hospitals of the Spanish national healthcare system: the PARADISE study",
        "Validation of a simple screening tool for early diagnosis of advanced Parkinson\u2019s disease in daily practice: the CDEPA questionnaire",
        "Letter to the editor, \u201cValidation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson\u2019s disease patients inadequately controlled on oral medications",
        "Timely referral for device-aided therapy in Parkinson\u2019s disease. Development of a screening tool",
        "PROBAST: A tool to assess risk of bias and applicability of prediction model studies: Explanation and elaboration",
        "A decision tool to support appropriate referral for deep brain stimulation in Parkinson\u2019s disease",
        "Referring Parkinson\u2019s disease patients for deep brain stimulation: a RAND/UCLA appropriateness study",
        "Choosing an advanced therapy in Parkinson\u2019s disease; is it an evidence-based decision in current practice?",
        "The patient\u2019s perspective on shared decision-making in advanced parkinson\u2019s disease: a cross-sectional survey study",
        "N\u00e4r tabletterna inte ger tillr\u00e4ckig effekt. SWEMODIS m\u00f6te 2017 om Parkinsons sjukdom i komplikationsfas",
        "Swedish guidelines for device-aided therapies in Parkinson\u2019s disease\u2014economic evaluation and implementation",
        "Levodopa\u2013entacapone\u2013carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: real-world experience and practical guidance",
        "Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson\u2019s disease: consensus from an international survey and discussion program",
        "Development and initial validation of a screening tool for Parkinson disease surgical candidates",
        "Identifying candidates for deep brain stimulation in Parkinson\u2019s disease: The role of the primary care physician",
        "Selection of deep brain stimulation candidates in private neurology practices: referral may be simpler than a computerized triage system",
        "Deep brain stimulation for Parkinson\u2019s disease - patient selection",
        "Device-assisted and neuromodulatory therapies for Parkinson\u2019s disease: a network meta-analysis",
        "Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view",
        "A review on response to device-aided therapies used in monogenic parkinsonism and GBA variants carriers: a need for guidelines and comparative studies",
        "5-2-1 criteria: a simple screening tool for identifying advanced PD patients who need an optimization of Parkinson\u2019s treatment",
        "Continuous drug delivery in Parkinson\u2019s disease",
        "Rationale and patient selection for interventional therapies in Parkinson\u2019s disease",
        "Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial",
        "Profile of patients with advanced Parkinson\u2019s disease suitable for device-aided therapies: restrospective data of a large cohort of Romanian patients",
        "Characterizing advanced Parkinson\u2019s disease: Romanian subanalysis from the OBSERVE-PD study",
        "Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease",
        "The spectrum effect in tests for risk prediction, screening, and diagnosis",
        "Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson\u2019s disease-the INfusion VErsus STimulation (INVEST) study",
        "A tool to improve pre-selection for deep brain stimulation in patients with Parkinson\u2019s disease",
        "Development and initial validation of the Chinese version of the Florida surgical questionnaire for Parkinson\u2019s disease",
        "Short- and long-term cost and utilization of health care resources in Parkinson\u2019s disease in the UK",
        "Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia",
        "Neurologist care in Parkinson disease: a utilization, outcomes, and survival study",
        "Managing Parkinson\u2019s disease with continuous dopaminergic stimulation",
        "When the going gets tough: How to select patients with Parkinson\u2019s disease for advanced therapies",
        "Barriers to Accessing Healthcare Services for People with Parkinson\u2019s Disease: A Scoping Review"
    ],
    "affiliation": [
        {
            "affiliation-city": "Groningen",
            "@id": "60006027",
            "affilname": "Universitair Medisch Centrum Groningen",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006027",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Copenhagen",
            "@id": "60025840",
            "affilname": "Bispebjerg Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025840",
            "affiliation-country": "Denmark"
        },
        {
            "affiliation-city": "Gda\u0144sk",
            "@id": "60012383",
            "affilname": "Gdanski Uniwersytet Medyczny",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012383",
            "affiliation-country": "Poland"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Gdansk",
            "@id": "129170965",
            "affilname": "St. Adalbert Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/129170965",
            "affiliation-country": "Poland"
        }
    ],
    "funding": [
        "Dutch Brain Foundation",
        "Michael J. Fox Foundation",
        "Dutch Heart Foundation",
        "University Medical Center Groningen"
    ]
}